NYSE:MRK
Merck & Company (MRK)
Financials 
Technical Analysis 
Jul 13, 2026, 12:00 amThis summary was created by AI, based on 22 opinions in the last 12 months.
Merck & Company (MRK) is regarded as a strong investment opportunity, primarily due to its robust drug pipeline and significant growth potential despite challenges with its blockbuster drug, Keytruda, which is set to go off-patent in 2028. Analysts highlight the company's anticipated increase in sales, particularly from Keytruda and other new drugs in development. While some concerns exist regarding market fluctuations and pricing clarity, a substantial number of experts maintain an optimistic outlook on the stock's performance. With a promising array of drugs poised for release by 2030 and solid financial metrics, including rising cash reserves and share buybacks, MRK is projected to see continued growth, making it a compelling choice for healthcare investors. Expert recommendations suggest a prudent approach to stop-loss levels and target price adjustments.
Today's downward move isn't all that outsized. There's been more clarity on US drug pricing. Seeing a bit of market exhaustion, as US pharma is trading at huge premiums relative to their own history.
Rerating from pricing clarity has already been baked in. R&D pipeline in the sector is a mixed bag, doesn't trust it.
He bought it for their strong drug pipeline and is happy to stay here.
Gordon ReidOne of her holdings in the space. This higher-quality name has both growth and less execution risk.
Brianne Gardner
;fill-opacity:1;'/%3e%3cpath%20d='M31%2018.6001V30H8V18.6001L14.1334%2022.4334L19.4999%2014L24.8669%2022.4334L31%2018.6001Z'%20fill='%23EE5432'%20style='fill:%23EE5432;fill:color(display-p3%200.9340%200.3310%200.1956);fill-opacity:1;'/%3e%3c/svg%3e){kind=small}
Premium contentPharmas are coming back. Political policy is improving. Keytruda makes up a lot of revenues but faces a patent cliff in 2028. But MRK has invested a lot in new drugs and been buying companies strategically.
(Analysts’ price target is $123.89)
Julien Nono-WomdimPremium content
They have a good pipeline that will help offset the loss of their major Keytruda drug when it goes off-patent. MRK is good at buying and tucking in companies. Their 2025 chart wasn't that great until the end of the year when the sector caught a bid.
Gordon Reid
Premium content
'%20fill='%23ffffff'%3e%3cg%20id='Pager'%20transform='translate(423.000000,%201755.000000)'%3e%3cpath%20d='M243.295367,17.286474%20C243.68919,16.9045087%20244.327703,16.9045087%20244.721525,17.286474%20L249,21.4361302%20L253.278475,17.286474%20C253.672297,16.9045087%20254.31081,16.9045087%20254.704633,17.286474%20C255.098456,17.6684393%20255.098456,18.2877274%20254.704633,18.6696927%20L249.35654,23.856763%20C249.159628,24.0477457%20248.840372,24.0477457%20248.64346,23.856763%20L243.295367,18.6696927%20C242.901544,18.2877274%20242.901544,17.6684393%20243.295367,17.286474%20Z'%20id='Path'%20transform='translate(249.000000,%2020.500000)%20rotate(-90.000000)%20translate(-249.000000,%20-20.500000)%20'%3e%3c/path%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e)
Popular Articles
Merck & Company (MRK) Frequently Asked Questions
What is Merck & Company stock symbol?
Merck & Company is a American stock, trading under the symbol MRK (previously MRK-N on Stockchase) on the New York Stock Exchange (MRK). It is usually referred to as NYSE:MRK or MRK
Is Merck & Company a buy or a sell?
In the last year, 22 stock analysts issued a Buy, Sell, or Hold rating on MRK (previously MRK-N on Stockchase). 16 analysts recommended to BUY and 3 analysts recommended to SELL the stock. The latest stock analyst rating is BUY. Read the latest stock experts' ratings for Merck & Company.
Is Merck & Company a good investment or a top pick?
Merck & Company was recommended as a Top Pick by Joe Terranova on 2025-11-17. Read the latest stock experts ratings for Merck & Company.
Why is Merck & Company stock dropping?
Earnings reports or recent company news can cause the stock price to drop. Read stock experts' recommendations for Merck & Company.
Is Merck & Company worth watching?
Merck & Company is followed by 311 investors on Stockchase and is a trending stock that is worth watching.
What is Merck & Company stock price?
On 2026-07-13, Merck & Company (MRK) stock closed at a price of $124.03.
'%20fill='%23FFB800'%3e%3cg%20id='filled-.-button'%20transform='translate(120.000000,%20413.999972)'%3e%3cpath%20d='M101.499729,2.82302245e-05%20C102.285413,-0.00432461793%20103.254164,0.496634241%20103.645655,1.25173399%20L103.712109,1.39623206%20L105.747863,6.45331817%20L111.028779,6.80428588%20C111.60867,6.84282525%20112.147242,7.1236355%20112.517275,7.58038413%20C113.223405,8.45199453%20113.142035,9.72214747%20112.357105,10.4940033%20L112.234099,10.6059323%20L108.072656,14.10894%20L109.356339,19.592529%20C109.472157,20.0872738%20109.394126,20.6085551%20109.13883,21.0455786%20C108.624329,21.9263208%20107.536956,22.2447485%20106.649713,21.8010736%20L106.511398,21.7246573%20L101.5,18.7715858%20L96.4886024,21.7246573%20C95.5790916,22.2767096%2094.4027498,21.9726757%2093.8611695,21.0455786%20C93.6058745,20.6085551%2093.5278433,20.0872738%2093.6436608,19.592529%20L94.9273443,14.10894%20L90.7659013,10.6059323%20C89.8680707,9.85015912%2089.7412886,8.49557505%2090.4827254,7.58038413%20C90.8527577,7.1236355%2091.39133,6.84282525%2091.9712215,6.80428588%20L97.2521374,6.45331817%20L99.2878908,1.39623206%20C99.6240254,0.561228427%20100.665516,-0.00460395016%20101.499729,2.82302245e-05%20Z'%20id='top-picks-.-icon-copy-7'%3e%3c/path%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e){kind=small}
'%3e%3cg%20id='filled-.-button'%20transform='translate(120.000000,%20413.999944)'%3e%3cg%20id='Group-8'%20transform='translate(90.000000,%200.000000)'%3e%3cpath%20d='M11.4997292,5.58581788e-05%20C12.2854126,-0.00429698998%2013.2541635,0.496661868%2013.6456551,1.25176162%20L13.7121092,1.39625969%20L15.7478626,6.4533458%20L21.0287785,6.8043135%20C21.60867,6.84285288%2022.1472423,7.12366313%2022.5172746,7.58041175%20C23.2234049,8.45202216%2023.142035,9.7221751%2022.3571045,10.4940309%20L22.2340987,10.60596%20L18.0726557,14.1089676%20L19.3563392,19.5925566%20C19.4721567,20.0873014%2019.3941255,20.6085828%2019.1388305,21.0456062%20C18.6243292,21.9263484%2017.5369557,22.2447761%2016.6497127,21.8011012%20L16.5113976,21.7246849%20L11.5,18.7716134%20L6.48860242,21.7246849%20C5.5790916,22.2767372%204.40274983,21.9727033%203.86116953,21.0456062%20C3.60587449,20.6085828%203.52784326,20.0873014%203.64366079,19.5925566%20L4.9273443,14.1089676%20L0.76590125,10.60596%20C-0.13192926,9.85018675%20-0.258711404,8.49560268%200.482725407,7.58041175%20C0.85275775,7.12366313%201.39132997,6.84285288%201.97122149,6.8043135%20L7.25213737,6.4533458%20L9.28789079,1.39625969%20C9.62402537,0.561256055%2010.6655161,-0.00457632221%2011.4997292,5.58581788e-05%20Z'%20id='top-picks-.-icon-copy-7'%20fill='%23FFB800'%3e%3c/path%3e%3cpath%20d='M11.4997292,2.77818228e-05%20C12.2854126,-0.00429698998%2013.2541635,0.496661868%2013.6456551,1.25176162%20L13.7121092,1.39625969%20L15.7478626,6.4533458%20L21.0287785,6.8043135%20C21.60867,6.84285288%2022.1472423,7.12366313%2022.5172746,7.58041175%20C23.2234049,8.45202216%2023.142035,9.7221751%2022.3571045,10.4940309%20L22.2340987,10.60596%20L18.0726557,14.1089676%20L19.3563392,19.5925566%20C19.4721567,20.0873014%2019.3941255,20.6085828%2019.1388305,21.0456062%20C18.6243292,21.9263484%2017.5369557,22.2447761%2016.6497127,21.8011012%20L16.5113976,21.7246849%20L11.5,18.7716134%20C11.4998195,6.25722299%2011.4997292,2.77818228e-05%2011.4997292,2.77818228e-05%20Z'%20id='top-picks-.-icon-copy-8'%20fill='%23EAEAEA'%3e%3c/path%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e){kind=small}
We reiterate MRK as a TOP PICK. Sales of its top cancer treatment drug, which accounts for the marjority of its revenues, is expected to more than triple its current $8 billion sales by 2028 and it has a long pipeline of new drugs, with plans to release over 20 by 2030. It trades at 23x earnings and supports a ROE of 27%. Cash reserves are growing, while shares are bought back, albeit with an increase in debt. We continue to recommend a stop at $110, looking to achieve $143 -- upside potential of 18%. Yield 2.7%
(Analysts’ price target is $131.56)